TMCnet News
Research and Markets: Global Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/jl72nk/pancreatic) has announced the addition of the "Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact Remains Distant" report to their offering. Poor Disease Prognosis (News - Alert) Due to Lack of Effective Treatment Options The current Pancreatic Cancer (PC) therapeutics market is very limited, with only four drugs approved for the treatment of the disease. These are the generics gemcitabine and fluorouracil (5-FU) and the patented drugs Tarceva, by Genentech and Roche, and Abraxane, by Celgene. Abraxane was approved by the US Food and Drug Administration (FDA) in September 2013 and by the European Medicines Agency (EMA (News - Alert)) in January 2014 (FDA, 2013). Since 1997, the standard of care in the treatment of advanced PC (aproximately 80% of patients are diagnosed with advanced disease) has been gemcitabine therapy, either as a monotherapy or in combination. In combination, gemcitabine is often prescribed with off-label drugs that cause minor improvements in progression-free survival, and trends towards (although not statistically significant) OS - for example, Xeloda and Eloxatin. Either in combination or as a monotherapy, average Overall Survival (OS) with gemcitabine-based therapy is six months, while the five-year survival rate is less than 5%. The recently approved Abraxane has been shown, when in combination with gemcitabine, to increase OS to 8.5 months (Von Hoff et al, 2011). The FOLFIRINOX regimen, which uses a combination of folinic acid, 5-FU, irinotecan and oxaliplatin, has been shown to increase OS in advanced PC patients to 11 months, but only in those with a good performance status. Even with Abraxane's and the FOLFIRINOX regimen's recent improvements in survival demonstrated with Abraxane and FOLFIRINOX, prognosis and survival chances are still substantially worse in PC than for other leading causes of cancer-related deaths, such as breast and lung cancer. There are noticeable gaps in treatment development, namely a lack of diagnostic tools and a lack of patient subset analysis and targeted therapies. As such, the marketed products are expected to remain dominated by gemcitabine and the off-label use of other chemotoxic agents, throughout the 2014-2020 forecast period. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products 4 Product Pipeline 5 Market Forecast 6 Deals 7 Appendix Products Mentioned
For more information visit http://www.researchandmarkets.com/research/jl72nk/pancreatic |
